These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

592 related items for PubMed ID: 27856088

  • 21. Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model.
    Bennett H, McEwan P, Hamilton K, O'Reilly K.
    BMC Nephrol; 2019 Apr 23; 20(1):136. PubMed ID: 31014270
    [Abstract] [Full Text] [Related]

  • 22. Urinary EGF Receptor Ligand Excretion in Patients with Autosomal Dominant Polycystic Kidney Disease and Response to Tolvaptan.
    Harskamp LR, Gansevoort RT, Boertien WE, van Oeveren W, Engels GE, van Goor H, Meijer E.
    Clin J Am Soc Nephrol; 2015 Oct 07; 10(10):1749-56. PubMed ID: 26231191
    [Abstract] [Full Text] [Related]

  • 23. Clinical Pattern of Tolvaptan-Associated Liver Injury in Trial Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD): An Analysis of Pivotal Clinical Trials.
    Alpers DH, Lewis JH, Hunt CM, Freston JW, Torres VE, Li H, Wang W, Hoke ME, Roth SE, Westcott-Baker L, Estilo A.
    Am J Kidney Dis; 2023 Mar 07; 81(3):281-293.e1. PubMed ID: 36191725
    [Abstract] [Full Text] [Related]

  • 24. Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease.
    Gansevoort RT, van Gastel MDA, Chapman AB, Blais JD, Czerwiec FS, Higashihara E, Lee J, Ouyang J, Perrone RD, Stade K, Torres VE, Devuyst O, TEMPO 3:4 Investigators.
    Kidney Int; 2019 Jul 07; 96(1):159-169. PubMed ID: 30898339
    [Abstract] [Full Text] [Related]

  • 25. Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-part, randomized, double-blind, placebo-controlled trial.
    Schaefer F, Mekahli D, Emma F, Gilbert RD, Bockenhauer D, Cadnapaphornchai MA, Shi L, Dandurand A, Sikes K, Shoaf SE.
    Eur J Pediatr; 2019 Jul 07; 178(7):1013-1021. PubMed ID: 31053954
    [Abstract] [Full Text] [Related]

  • 26. Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptan treatment in patients with autosomal dominant polycystic kidney disease.
    Horie S, Muto S, Kawano H, Okada T, Shibasaki Y, Nakajima K, Ibuki T.
    Clin Exp Nephrol; 2021 May 07; 25(5):467-478. PubMed ID: 33471240
    [Abstract] [Full Text] [Related]

  • 27. Association of plasma somatostatin with disease severity and progression in patients with autosomal dominant polycystic kidney disease.
    Messchendorp AL, Spithoven EM, Casteleijn NF, Dam WA, van den Born J, Tonnis WF, Gaillard CAJM, Meijer E, DIPAK Consortium.
    BMC Nephrol; 2018 Dec 19; 19(1):368. PubMed ID: 30567514
    [Abstract] [Full Text] [Related]

  • 28. Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease.
    Boertien WE, Meijer E, de Jong PE, Bakker SJ, Czerwiec FS, Struck J, Oberdhan D, Shoaf SE, Krasa HB, Gansevoort RT.
    Kidney Int; 2013 Dec 19; 84(6):1278-86. PubMed ID: 23903369
    [Abstract] [Full Text] [Related]

  • 29. Efficacy and safety of tolvaptan versus placebo in the treatment of patients with autosomal dominant polycystic kidney disease: a meta-analysis.
    Lu J, Xu W, Gong L, Xu M, Tang W, Jiang W, Xie F, Ding L, Qian X.
    Int Urol Nephrol; 2023 Mar 19; 55(3):631-640. PubMed ID: 36069961
    [Abstract] [Full Text] [Related]

  • 30. Tolvaptan for Children and Adolescents with Autosomal Dominant Polycystic Kidney Disease: Randomized Controlled Trial.
    Mekahli D, Guay-Woodford LM, Cadnapaphornchai MA, Greenbaum LA, Litwin M, Seeman T, Dandurand A, Shi L, Sikes K, Shoaf SE, Schaefer F.
    Clin J Am Soc Nephrol; 2023 Jan 01; 18(1):36-46. PubMed ID: 36719158
    [Abstract] [Full Text] [Related]

  • 31. Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience.
    Higashihara E, Torres VE, Chapman AB, Grantham JJ, Bae K, Watnick TJ, Horie S, Nutahara K, Ouyang J, Krasa HB, Czerwiec FS, TEMPOFormula and 156-05-002 Study Investigators.
    Clin J Am Soc Nephrol; 2011 Oct 01; 6(10):2499-507. PubMed ID: 21903984
    [Abstract] [Full Text] [Related]

  • 32. Safety and efficacy of Tolvaptan in real-world patients with autosomal dominant polycystic kidney disease- interim results of SLOW-PKD surveillance.
    Mochizuki T, Muto S, Miyake M, Tanaka T, Wang W.
    Clin Exp Nephrol; 2021 Nov 01; 25(11):1231-1239. PubMed ID: 34228250
    [Abstract] [Full Text] [Related]

  • 33. Effect of tolvaptan in Japanese patients with autosomal dominant polycystic kidney disease: a post hoc analysis of TEMPO 3:4 and TEMPO Extension Japan.
    Muto S, Okada T, Shibasaki Y, Ibuki T, Horie S.
    Clin Exp Nephrol; 2021 Sep 01; 25(9):1003-1010. PubMed ID: 34089122
    [Abstract] [Full Text] [Related]

  • 34. Effectiveness of Tolvaptan in the Treatment for Patients with Autosomal Dominant Polycystic Kidney Disease: A Meta-analysis.
    Xie X, Cai Q, Guo XY, Bai DH, Sheng HZ, Wang BK, Yan K, Lu AM, Wang XR.
    Comb Chem High Throughput Screen; 2020 Sep 01; 23(1):6-16. PubMed ID: 31793415
    [Abstract] [Full Text] [Related]

  • 35. Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease.
    Irazabal MV, Torres VE, Hogan MC, Glockner J, King BF, Ofstie TG, Krasa HB, Ouyang J, Czerwiec FS.
    Kidney Int; 2011 Aug 01; 80(3):295-301. PubMed ID: 21544064
    [Abstract] [Full Text] [Related]

  • 36. Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database.
    Watkins PB, Lewis JH, Kaplowitz N, Alpers DH, Blais JD, Smotzer DM, Krasa H, Ouyang J, Torres VE, Czerwiec FS, Zimmer CA.
    Drug Saf; 2015 Nov 01; 38(11):1103-13. PubMed ID: 26188764
    [Abstract] [Full Text] [Related]

  • 37. Urinary Lithogenic Risk Profile in ADPKD Patients Treated with Tolvaptan.
    Bargagli M, Dhayat NA, Anderegg M, Semmo M, Huynh-Do U, Vogt B, Ferraro PM, Fuster DG.
    Clin J Am Soc Nephrol; 2020 Jul 01; 15(7):1007-1014. PubMed ID: 32527945
    [Abstract] [Full Text] [Related]

  • 38. Potential effect of tolvaptan on polycystic liver disease for patients with ADPKD meeting the Japanese criteria of tolvaptan use.
    Mizuno H, Sekine A, Suwabe T, Ikuma D, Yamanouchi M, Hasegawa E, Sawa N, Ubara Y, Hoshino J.
    PLoS One; 2022 Jul 01; 17(2):e0264065. PubMed ID: 35176098
    [Abstract] [Full Text] [Related]

  • 39. Visceral Adiposity and Progression of ADPKD: A Cohort Study of Patients From the TEMPO 3:4 Trial.
    Nowak KL, Moretti F, Bussola N, Steele CN, Gregory AV, Kline TL, Ramanathan S, Trapletti G, Furlanello C, McCormick L, Chonchol M.
    Am J Kidney Dis; 2024 Sep 01; 84(3):275-285.e1. PubMed ID: 38608748
    [Abstract] [Full Text] [Related]

  • 40. Sodium and urea excretion as determinants of urine output in autosomal dominant polycystic kidney disease patients on V2 receptor antagonists: impact of dietary intervention.
    Côté G, Asselin-Thompstone L, Mac-Way F, René de Cotret P, Lacroix C, Desmeules S, Agharazii M.
    Int Urol Nephrol; 2020 Feb 01; 52(2):343-349. PubMed ID: 32008201
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 30.